Last $0.85 USD
Change Today -0.0149 / -1.73%
Volume 100.7K
PTN On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:04 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

palatin technologies inc (PTN) Key Developments

Palatin Technologies Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended March 31, 2014

Palatin Technologies Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended March 31, 2014. For the quarter, the company reported loss from operations was of $3,363,738 compared to $4,023,784 for the same period a year ago. Loss before income taxes were $3,359,557 compared to $4,015,258 for the same period a year ago. Net loss was $1,512,911 or $0.01 per and diluted share compared to $4,015,258 or $0.04 per basic and diluted share for the same period a year ago. The decrease in net loss for the quarter ended March 31, 2014, compared to the same period last fiscal year, is primarily attributable to the recognition of $1.85 million in tax benefits in the quarter ended March 31, 2014. For nine months, the company reported loss from operations was of $11,466,826 compared to $10,865,060 for the same period a year ago. Loss before income taxes were $11,455,200 compared to $17,897,334 for the same period a year ago. Net loss was $9,608,554 or $0.09 per and diluted share compared to $16,144,126 or $0.17 per basic and diluted share for the same period a year ago.

Palatin Technologies Inc. to Report Q3, 2014 Results on May 13, 2014

Palatin Technologies Inc. announced that they will report Q3, 2014 results at 7:30 AM, US Eastern Standard Time on May 13, 2014

Palatin Technologies Inc., Q3 2014 Earnings Call, May 13, 2014

Palatin Technologies Inc., Q3 2014 Earnings Call, May 13, 2014

Palatin Technologies Inc., Annual General Meeting, Jun 19, 2014

Palatin Technologies Inc., Annual General Meeting, Jun 19, 2014., at 09:30 US Eastern Standard Time. Location: Palatin's offices, Cedar Brook Corporate Center. Agenda: To consider election of nine directors nominated by board of directors; to consider ratification of appointment of independent registered public accounting firm for the fiscal year ending June 30, 2014; to approve the compensation of named executive officers (say-on-pay); and to consider any other matters properly brought before the meeting or any adjournment or postponement thereof.

Palatin Technologies, Inc. Announces Positive Data from Phase IIb Female Sexual Dysfunction Trial

Palatin Technologies Inc. announced new analyses from its Phase IIb clinical trial of bremelanotide, which demonstrated dose-dependent improvements in sexual desire and treatment satisfaction in premenopausal women with hypoactive sexual desire disorder (HSDD) and combined HSDD/female sexual arousal disorder (FSAD). Bremelanotide is a first-in-class, investigative melanocortin agonist being developed for treatment of female sexual dysfunction (FSD). In one abstract, responder analyses showed bremelanotide had a statistically significant increase in the percentage of women whose total score on the Female Sexual Function Index (FSFI) - a measure of overall sexual functioning - improved: 69% for 1.75 mg versus 46% for placebo (p<0.05). In addition, a significantly higher percentage of women on bremelanotide versus placebo achieved at least one satisfying sexual event (SSE): 55% for 1.75 mg versus 37% for placebo (p<0.05). A second abstract, presenting data from the episodic questionnaire, Female Sexual Encounter Profile - Revised (FSEP-R), demonstrated greater mean increases in SSEs within 24 hours of dosing with bremelanotide 1.75 mg (mean increase: 0.7; p=0.0443) versus placebo (mean increase: 0.1). As-needed administration of bremelanotide 1.75 mg versus placebo also demonstrated episodic increases in levels of desire (0.4 vs. 0.0, respectively) and in the women's satisfaction with their levels of desire (0.6 vs. 0.1, respectively). In a third abstract, data collected from the Women's Inventory of Treatment Satisfaction (WITS-9) showed women who completed treatment were significantly more satisfied with bremelanotide 1.75 mg (0.77; p=0.0204) versus placebo (0.17).

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PTN:US $0.85 USD -0.0149

PTN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PTN.
View Industry Companies
 

Industry Analysis

PTN

Industry Average

Valuation PTN Industry Range
No financial data is available for PTN.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PALATIN TECHNOLOGIES INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.